Table 5.

Absolute number and percentage of circulating CD19- and CD20-positive B cells at different time points from rituximab infusiona

Months
0123612
Retrospective
    TI ≥ 1.7
        CD19 (n)280.0 ± 199.710.3 ± 4.411.8 ± 5.114.3 ± 8.436.4 ± 42.5148.4 ± 138.3
        CD19 (%)13.4 ± 3.30.7 ± 0.80.8 ± 0.51.0 ± 0.83.0 ± 2.17.2 ± 5.4
        CD20 (n)225.4 ± 154.60.8 ± 1.12.7 ± 2.510.3 ± 12.013.2 ± 14.754.4 ± 62.3
        CD20 (%)11.1 ± 2.20.0 ± 0.00.0 ± 0.00.7 ± 0.91.3 ± 0.72.4 ± 1.9
    TI < 1.7
        CD19 (n)225.6 ± 83.76.0 ± 3.75.3 ± 4.220.1 ± 20.053.0 ± 28.6137.1 ± 88.3
        CD19 (%)13.0 ± 0.70.2 ± 0.40.3 ± 0.60.7 ± 1.03.0 ± 1.97.0 ± 3.5
        CD20 (n)161.0 ± 89.91.2 ± 1.826.5 ± 27.434.0 ± 18.363.5 ± 51.9101.6 ± 89.3
        CD20 (%)7.9 ± 3.20.0 ± 0.01.4 ± 1.22.7 ± 2.33.1 ± 1.95.1 ± 4.2
Prospective (TI < 1.7)
    CD19 (n)358.5 ± 120.96.8 ± 9.430.2 ± 36.025.2 ± 37.510.6 ± 7.642.5 ± 37.5
    CD19 (%)15.5 ± 6.40.5 ± 0.80.6 ± 0.51.2 ± 1.20.6 ± 0.53.5 ± 3.5
    CD20 (n)165.5 ± 20.53.5 ± 2.120.6 ± 25.913.5 ± 18.46.3 ± 7.132.0 ± 32.5
    CD20 (%)7.8 ± 4.70.7 ± 0.40.5 ± 0.50.4 ± 0.50.9 ± 0.72.7 ± 3.0
  • a Data are mean ± SD. Normal ranges at our laboratory: CD19 (n: 35 to 506 cell/mm3; %: 3 to 22), CD20 (n: 61 to 574 cell/mm3; %: 4 to 25).